Combination therapy of erythromycin and metoclopramide increases feeding success in critically ill patientsCombination Therapy Shows Better Feeding Success for Critically Ill Patients

Frontiers in Medicine Published September 12, 2026 DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider combination therapy for improved feeding success, but note the superior safety profile of metoclopramide.

This systematic review and network meta-analysis evaluated the efficacy and safety of erythromycin, metoclopramide, and combination therapy for managing feeding in critically ill patients. The analysis included 17 studies with a total sample size of 2,654 patients. The primary finding was that combination therapy was the most effective for feeding success, with an OR of 3.03 (95% CI [1.90-4.83]) compared to erythromycin and an OR of 4.89 (95% CI [3.01-7.93]) compared to metoclopramide.

Secondary outcomes, including postpyloric intubation success, gastric residual volume (GRV) change, and adverse events (AEs), showed less definitive results. Postpyloric intubation success showed no significant pairwise differences with a SUCRA of 76.4% for combination therapy. Safety data indicated that placebo (SUCRA 80.0%) and metoclopramide (65.6%) had more favorable safety profiles than combination therapy (7.5%).

Several limitations were noted, including small trial sizes for feeding success, very wide confidence intervals for postpyloric intubation success, and low certainty for AEs and GRV. While combination therapy may be more effective for feeding success, the superior safety profile of metoclopramide must be considered in clinical practice. These preliminary findings require confirmation in larger, well-designed trials.

How this fits prior evidence

This finding addresses a gap in managing nutritional support for critically ill patients. While previous evidence confirmed that high-protein supplementation does not reduce mortality in critical illness, this study specifically addresses the pharmacological management of feeding success. The results suggest that while combination therapy improves feeding success, it may carry a higher risk of adverse events compared to metoclopramide monotherapy.

This review looked at 2,654 critically ill patients across 17 different studies. Researchers compared three approaches: using erythromycin alone, using metoclopramide alone, or using a combination of both medications to help with feeding success.

The results showed that the combination therapy was the most effective for successful feeding. Patients receiving both medications were significantly more likely to have successful feeding compared to those receiving only erythromycin or only metoclopramide. However, the study did not find significant differences between the groups regarding gastric residual volume or postpyloric intubation success.

There is an important note regarding safety. While the combination therapy was more effective for feeding, metoclopramide and placebo groups had better safety profiles than the combination group. Because some of the original studies were small and the evidence for safety is not very certain, these results should be viewed as an association rather than a definitive rule. Patients and doctors should discuss these findings to determine the best treatment plan based on individual needs.

What this means for you:

Combination therapy may improve feeding success in critically ill patients, but it may have a less favorable safety profile.

Common questions

Is the combination of erythromycin and metoclopramide effective?

The study found that combination therapy was the most effective for feeding success. Patients receiving both medications were significantly more likely to have successful feeding compared to those receiving only erythromycin or only metoclopramide. However, the evidence for other outcomes like gastric residual volume was not clear.

Are there safety concerns with the combination therapy?

The study noted that metoclopramide and placebo had more favorable safety profiles than the combination therapy. While the combination was more effective for feeding, it was associated with more adverse events in the data. You should talk to a doctor about the best safety profile for a specific patient.

Who is this finding relevant for?

These findings are relevant for the management of critically ill patients who require nutritional support. The study specifically looked at 2,654 patients to determine which medication approach best supported successful feeding in a critical care setting.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedSep 2026

View Original Abstract ↓

BackgroundThe comparative effectiveness and safety of erythromycin, metoclopramide, and their combination for enteral nutrition in critically ill patients remain uncertain. This network meta-analysis (NMA) synthesized available evidence.MethodsA systematic search of seven electronic databases (Embase, PubMed, Web of Science, Cochrane Library, CNKI, Wanfang, VIP) from inception to February 6, 2026, was conducted with no language restrictions. Standard Cochrane methods were used for study selection, data extraction, and risk of bias assessment. A frequentist NMA was performed using STATA 18.0 with the mvmeta package. Effect estimates were calculated as odds ratios (OR) for binary outcomes and mean differences (MD) for gastric residual volume (GRV), each with 95% confidence intervals (CI). Random-effects models were used throughout. The surface under the cumulative ranking curve (SUCRA) was used to rank interventions. Sensitivity analyses excluded two pediatric studies. Certainty of evidence was assessed using the CINeMA framework (GRADE for NMA).ResultsSeventeen studies (2,654 patients) were included. For feeding success (5 trials), combination therapy was most effective [SUCRA 100.0%; OR vs. erythromycin 3.03 (1.90–4.83); vs. metoclopramide 4.89 (3.01–7.93)]. For postpyloric intubation success (10 trials), no significant pairwise differences were found; combination therapy ranked highest (SUCRA 76.4%) but with very wide confidence intervals. GRV change (3 trials) showed no significant differences. For any reported AEs (12 trials), placebo (SUCRA 80.0%) and metoclopramide (65.6%) had the most favorable safety profiles, while combination therapy ranked worst (7.5%). The certainty of evidence was moderate for feeding success, low to moderate for AEs, and very low for postpyloric intubation success and GRV.ConclusionCombination therapy may be the most effective for feeding success, though based on small trials. Metoclopramide had a better safety profile. No significant differences were observed for postpyloric intubation success or GRV. These preliminary findings require confirmation in larger, well-designed trials.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD420251247900.

Combination therapy of erythromycin and metoclopramide increases feeding success in critically ill patientsCombination Therapy Shows Better Feeding Success for Critically Ill Patients

How this fits prior evidence

Common questions

Study Details

Sitagliptin and liraglutide superior for CGM targets in type 2 diabetes

Two diabetes drugs outperform others in long-term glucose control

Clinical research that matters. Delivered to your inbox.

Combination therapy of erythromycin and metoclopramide increases feeding success in critically ill patientsCombination Therapy Shows Better Feeding Success for Critically Ill Patients

How this fits prior evidence

Common questions

More on erythromycin

Study Details

Sitagliptin and liraglutide superior for CGM targets in type 2 diabetes

Two diabetes drugs outperform others in long-term glucose control

Clinical research that matters. Delivered to your inbox.

Related in Nutrition & Obesity Medicine

From Other Specialties